Keep an eye on Viking Therapeutics (VKTX). While the obesity drug stock has already exploded, it could see higher highs.
At the moment, Viking Therapeutics and its potential obesity treatment – VK2735, has already shown a mean weight loss of up to 18 pounds from baseline. The company also initiated a Phase 1 clinical study to evaluate a novel oral formulation of VK2735. The company believes the potential to provide both a subcutaneously injected and an oral dosage form represents a significant expansion of the opportunity for VK2735.
Better, there’s growing speculation of a potential takeover. Plus, the company now says it will have study results before the end of the first quarter, and not “sometime in the first half of the year,” according to Investors’ Business Daily.
VKTX last traded at $36.20. From here, if obesity drug data is solid, VKTX could potentially test $50 a share.
Sincerely.
Ian Cooper
Recent Comments